Cohen says while the data from the study looking at nivolumab has not been released yet, the halting of the trial due it having met its primary OS endpoint likely means good news.
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the early halting of the CheckMate-141 trial. The trial is looking at nivolumab (Opdivo) and its ability to boost overall survival (OS) in patients with in platinum-refractory squamous cell carcinoma of the head and neck (SCCHN).
Cohen says while the data from the study has not been released yet, the halting of the trial due it having met its primary overall survival (OS) endpoint likely means good news. He adds that considering the standard therapies in the current second-line setting currently have a "dismal" progression-free survival and OS for patients, the addition of nivolumab would greatly benefit patients.
According to a recent press release from the drug's manufacturer Bristol-Myers Squibb, the study was stopped after a panel determined the primary endpoint was met with nivolumab versus investigator's choice of cetuximab, methotrexate, or docetaxel.